Abstract
There is an urgent need to identify reliable biomarkers that can be used in early diagnosis, prognostication prediction and as possible therapeutic targets for lung cancer due to its current poor prognosis. Long noncoding RNAs (lncRNAs) have recently attracted additional attention due to their potential role in carcinogenesis, invasion and metastasis. Issues involved in the biofunctions and regulatory mechanisms of oncogenic and tumor-suppressive lncRNAs in lung cancer are discussed. Some lncRNAs have shown good diagnostic value, especially in combination with conventional serum protein markers. The use of antisense oligonucleotides, small molecules and RNA interference techniques have shown promise as direct therapeutic tools for targeting lncRNAs in preclinical studies. The biomarker function of lncRNAs may also indirectly involved in tumor therapy as a reference to conventional therapy. Overall, the concept of using lncRNAs as biomarkers for prognostication and intervention in lung cancer is still in its infancy, and only with more in-depth studies could they have a significant impact.
Author supplied keywords
Cite
CITATION STYLE
Chen, L., Xie, Y., Yu, M., & Gou, Q. (2022). Long Noncoding RNAs in Lung Cancer: From Disease Markers to Treatment Roles. Cancer Management and Research, 14, 1771–1782. https://doi.org/10.2147/CMAR.S365762
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.